IL1B and systemic lupus erythematosus: Treatment with epigallocatechin-3-gallate (EGCG) mitigates disease severity, such as renal impairment in lupus-prone mice by anti-inflammatory effects, including the reduction of nuclear factor kappa B (NF-κB) activation, the expression of NLRP3, IL-1β, and IL-18, and the enhancement of regulatory T (Treg) cell activity [28].